Neovasc, a specialty vascular device company that develops medical devices for the vascular and surgical marketplace, has reported an improvement in a patient’s angina symptoms six months following implantation of its Reducer device.
The Reducer is implanted in the coronary sinus vein using minimally invasive techniques.
By altering blood flow in the coronary sinus, the Reducer acts to increase the perfusion of oxygenated blood to certain areas of the heart muscle, thereby reducing the pain and disability caused by the condition.
At baseline the patient demonstrated significant ischemia of the heart muscle in certain areas around the left ventricle as measured using echo dobutamine stress testing.
At follow-up testing, these areas appeared substantially normal, with no significant ischemia observed.
Neovasc medical director Shmuel Banai said while representing only a single patient, these encouraging results illustrate the potential of the Reducer device to provide relief of angina symptoms and are also consistent with the positive data reported in the initial Reducer studies.
Neovasc is presently enrolling patients in the coronary sinus reducer for treatment of refractory angina (COSIRA) trial.
COSIRA, a multicenter, sham-controlled, randomized, double-blinded study, is designed to provide controlled, statistically significant data to further demonstrate the efficacy of the Reducer product to support regulatory applications and marketing for the millions of refractory angina patients who could potentially benefit.